TABLE 3.
Darbe, n = 33 | Epo, n = 33 | Placebo, n = 33 | P1 = | P2 = | |
---|---|---|---|---|---|
Transfusions/subject | 1.2 ± 2.4 | 1.2 ± 1.6 | 2.4 ± 2.9 | .015 | .949 |
0 [0, 1] | 0 [0, 2] | 1 [0, 4] | |||
Donors/subject | 0.7 ± 1.2 | 0.8 ± 1.0 | 1.2 ± 1.3 | .044 | .558 |
0 [0, 1] | 0 [0, 2] | 1 [0, 2] | |||
Volume, mL/kg | 30 ± 58 | 23 ± 33 | 51 ± 65 | .041 | .600 |
0 [0, 29.2] | 0 [0, 36.6] | 20.0 [0, 87.9] | |||
Volume, mL/kg, transfused subjects only | 75.6 ± 73.2 | 48.0 ± 32.7 | 80.7 ± 65.3 | .36 | .61 |
45 [20.0, 102.4] | 39.8 [21.5, 65.7] | 83.3 [20.0, 97.8] | |||
Subjects not transfused, n (%) | 20 (59%) | 17 (52%) | 12 (38%) | .088 | .620 |
Transfusion protocol violations/transfused subject, total | 0.8 ± 1.7 | 1.1 ± 1.1 | 0.9 ± 1.4 | .805 | .661 |
0 [0, 1] | 1 [0, 1] | 0 [0, 1] | |||
Due to high hematocrit | 0.7 ± 1.7 | 0.8 ± 1.1 | 0.5 ± 1.3 | .435 | .895 |
0 [0, 1] | 0.5 [0, 1] | 0 [0, 0] | |||
Due to low transfusion volume | 0.2 ± 0.4 | 0.3 ± 0.8 | 0.4 ± 0.6 | .300 | .381 |
0 [0, 0] | 0 [0, 0] | 0 [0, 1] | |||
Total phlebotomy losses, mL/kg | 32.3 [20.3–42.5] | 29.9 [20.4–42.5] | 24.9 [20.4–53.0] | .732 | .802 |
43.7 ± 45.3 | 42.5 ± 31.0 | 55.9 ± 53.9 | |||
Pre study | 3.6 [1.6–7.2] | 5.8 [3.4–8.9] | 6.4 [3.7–9.0] | .137 | .267 |
5.6 ± 6.5 | 6.1 ± 4.4 | 7.9 ± 7.5 | |||
During study | 32.3 [20.3–42.5] | 29.9 [20.4–42.5] | 24.9 [20.4–53.0] | .974 | .801 |
37.7 ± 43.1 | 35.5 ± 30.7 | 46.9 ± 49.5 | |||
Post study | 0 [0–0] | 0.2 [0–1.3] | 0.3 [0–1.0] | .191 | .015 |
0.5 ± 1.1 | 0.9 ± 2.0 | 1.1 ± 2.1 |
Values represent mean ± SD and median [first quartile, third quartile]. Phlebotomy losses are represented by 95% confidence intervals. P1, Darbe plus Epo (combined) versus placebo; P2, Darbe versus Epo